<a href="https://www.fiercebiotech.com/biotech/british-biotech-vc-funding-shows-signs-recovery-ipo-rebound-yet-materialize" hreflang="en">British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize</a>
British biotech funding has seen a promising recovery, with £552 million raised in Q1 2026, up from £466 million in Q4 2025, indicating a more active investment environment; however, the anticipated rebound in IPOs has not yet occurred, as no new public listings were recorded during the quarter.
The key insight for you is that while British biotech VC funding is showing signs of recovery with increased investment across various stages, the IPO market remains stagnant without any new public listings in Q1 2026. This situation presents a potential opportunity to explore acquisitions in the UK biotech sector, as evidenced by recent significant deals by Eli Lilly and Amgen, indicating strong international demand for UK biotech assets despite challenging financing conditions.